株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腸チフスワクチン市場: 市場機会分析および将来予測

Typhoid Fever Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026

発行 Coherent Market Insights 商品コード 817595
出版日 ページ情報 英文 177 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=107.66円で換算しております。
Back to Top
腸チフスワクチン市場: 市場機会分析および将来予測 Typhoid Fever Vaccines Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
出版日: 2019年03月15日 ページ情報: 英文 177 Pages
概要

当レポートでは、腸チフスワクチンの世界市場を調査し、市場の概要、タイプ、地域別の市場動向、市場規模の推移と予測、市場促進・阻害要因ならびに市場機会の分析、競合情勢、主要企業のプロファイルなど包括的な情報を提供しています。

目次

第1章 調査目的と前提条件

    • 調査目的
    • 前提条件
    • 略語

第2章 市場の概要

    • レポートの説明
    • 市場の定義と範囲
    • エグゼクティブサマリー
    • 市場スニペット:ワクチンタイプ別
    • 市場スニペット:投与経路別
    • 市場スニペット:地域別
    • コヒーレントオポチュニティマップ(COM)

第3章 市場のダイナミクス、規制、動向分析

    • マーケットダイナミクス
    • 成長要因
    • 阻害要因
    • 市場機会
    • 影響分析
    • 新製品の発売/承認
    • PEST分析
    • 意識向上戦略
    • 還付シナリオ
    • 腸チフスワクチン不足
    • 臨床試験分析
    • 蛇咬傷の発生率が高い国
    • 市場参入の課題

第4章 腸チフスワクチン市場:タイプ別

    • イントロダクション
    • 市場シェア分析、2018年・2026年(%)
    • 成長の分析、2017年-2026年
    • セグメント動向
    • 弱毒化生ワクチン
    • 莢膜多糖ワクチン
    • 共役ワクチン
    • その他

第5章 腸チフスワクチン市場:投与経路別

    • イントロダクション
    • 市場シェア分析、2018年・2026年(%)
    • 成長の分析、2017年-2026年
    • セグメント動向
    • 経口
    • 非経口

第6章 腸チフスワクチン市場:地域別

    • イントロダクション
    • 市場シェア分析:地域別、2018年・2026年(%)
    • 地域別、2017年 - 2026年の成長分析
    • 北米
    • 欧州
    • アジア太平洋
    • 中南米
    • アフリカ
    • 中東

第7章 競争環境

    • ヒートマップ解析
    • 企業プロファイル
    • GlaxoSmithKline Plc.
    • Sanofi SA
    • Bharat Biotech
    • Bio-Med Pvt. Ltd.
    • PT Bio Farma
    • PaxVax, Inc.
    • Shanghai Institute of Biological Products Co., Ltd.
    • Prokarium

第8章 セクション

    • 参考文献
    • 調査方法
    • Coherent Market Insightsについて
目次

Typhoid fever is a bacterial infection caused by Salmonella typhi, which causes symptoms such as prolonged fever, headache, nausea, loss of appetite, and constipation or sometimes diarrhea. Typhoid fever is majorly caused in area with poor sanitation and lack of clean drinking water. Typhoid fever vaccines are the biological formulation, which provide immunity and protects an individual against typhoid fever

Currently there are three typhoid vaccines recommended World Health organization (WHO) for use which include:

  • Injectable typhoid conjugate vaccine (TCV), consisting of Vi polysaccharide antigen linked to tetanus toxoid protein licensed for children from 6 months of age and adults up to 45 years of age;
  • Injectable unconjugated polysaccharide vaccine based on the purified Vi antigen (known as Vi-PS vaccine) for persons aged two years and above; and
  • Oral live attenuated Ty21a vaccine in capsule formulation for those over six years of age.

Market Dynamics

High prevalence of typhoid fever in region such as Asia Pacific and Africa is expected to drastically rise demand for its vaccines and support global typhoid fever vaccines market growth over the forecast period.

For instance, according to the data published by World Health Organization (WHO) in September 2018, globally between 11 and 21 million cases of typhoid were found, which caused around 128 000 to 161 000 typhoid-related deaths occur annually.

According to the data published by National Center for Biotechnology Information (NCBI) in 2018, incidence of typhoid fever in Africa was estimated to be 10-100 cases per 100,000

Increasing initiatives by government and various other organizations to increase awareness about typhoid vaccine and rising access of new vaccines is expected to support typhoid fever vaccines market growth during forecast period.

For instance, in February 2019, Gavi, the Vaccine Alliance in partnership with WHO, CDC and Zimbabwe's Ministry of Health launched a campaign to tackle typhoid outbreak in Zimbabwe. The campaign aims to vaccinate 325,000 people in nine suburbs of Zimbabwe's capital with new typhoid conjugate vaccine (TCV).

Key features of the study:

  • This report provides in-depth analysis of Typhoid fever vaccines market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 - 2026), considering 2017, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global Typhoid fever vaccines market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include GlaxoSmithKline Plc., Sanofi SA, Bharat Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, PaxVax, Inc. Shanghai Institute of Biological Products Co., Ltd., and Prokarium.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Typhoid fever vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the Typhoid fever vaccines market

Detailed Segmentation:

  • Global Typhoid Fever Vaccines Market, By Vaccine Type :
    • Live Attenuated Vaccine
    • Capsular Polysaccharide Vaccines
    • Conjugate Vaccine
    • Others
  • Global Typhoid Fever Vaccines Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Typhoid Fever Vaccines Market, By Geography:
    • North America
      • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
      • By Route of Administration:
      • Oral
      • Parenteral
      • By Country:
      • U.S.
      • Canada
    • Europe
      • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
      • By Route of Administration:
      • Oral
      • Parenteral
      • By Country:
      • U.K.
      • Germany
      • Italy
      • France
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
      • By Route of Administration:
      • Oral
      • Parenteral
      • By Country:
      • China
      • India
      • Japan
      • ASEAN
      • Australia
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
      • By Route of Administration:
      • Oral
      • Parenteral
      • By Country:
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Middle East
      • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
      • By Route of Administration:
      • Oral
      • Parenteral
      • By Country:
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Vaccine Type :
      • Live Attenuated Vaccine
      • Capsular Polysaccharide Vaccines
      • Conjugate Vaccine
      • Others
      • By Route of Administration:
      • Oral
      • Parenteral
      • By Country:
      • Central Africa
      • South Africa
      • North Africa
  • Company Profiles
    • GlaxoSmithKline Plc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Sanofi SA
    • Bharat Biotech
    • Bio-Med Pvt. Ltd.
    • PT Bio Farma
    • PaxVax, Inc.
    • Shanghai Institute of Biological Products Co., Ltd.
    • Prokarium
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Vaccine Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Novel Product Launch/Approval
    • PEST Analysis
    • Awareness Strategy
    • Reimbursement Scenario
    • Typhoid Fever Vaccines Shortage
    • Clinical Trial Analysis
    • Countries with High Number of Incidents of Snake Bites
    • Market Entry Challenges

4. Global Typhoid Fever Vaccines Market, By Vaccine Type, 2016 - 2026 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Live Attenuated Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Capsular Polysaccharide Vaccines
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Conjugate Vaccine
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

5. Global Typhoid Fever Vaccines Market, By Route of Administration, 2016 - 2026 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, 2017-2026
    • Segment Trends
    • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)
    • Parental
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2026, (US$ Mn)

6. Global Typhoid Fever Vaccines Market, By Region, 2016 - 2026 (US$ Mn)

    • Introduction
    • Market Share Analysis, By Region, 2018 and 2026 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017-2026
    • North America
    • Market Size and Forecast, By Vaccine Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Vaccine Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Vaccine Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
    • Latin America
    • Market Size and Forecast, By Vaccine Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Vaccine Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Vaccine Type, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2026 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2026 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

7. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • GlaxoSmithKline Plc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Sanofi SA
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bharat Biotech
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Bio-Med Pvt. Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • PT Bio Farma
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • PaxVax, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Shanghai Institute of Biological Products Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Prokarium
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

8. Section

    • References
    • Research Methodology
    • About us and Sales Contact
Back to Top